{"filings":[{"id":3412522,"accession_number":"0001493152-26-046738","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-10-13T12:00:19+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CDT Equity raises $6.75M convertible note from J.J. Astor; 225K warrants at $0.9177","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $6.75M senior secured convertible note to J.J. Astor & Co.; first tranche $3.0M funded (net $2,869,850), second $2.0M subject to conditions by Dec 31, 2026.","Note matures March 24, 2027; 24 weekly installments of $168,750 starting Oct 14, 2026; default interest 24% and 120% default principal.","Warrants for 225,000 shares at $0.9177 exercisable immediately, expire 5 years; conversion price 70% of lowest 20-day VWAP or $0.18354 floor.","80% of ATM proceeds from A.G.P. sales on/after Oct 6, 2026 must first repay note; 100% of resale/financing proceeds also applied.","Stockholder approval required for conversion/warrant shares; meeting no later than Nov 13, 2026; lender conversion capped at 4.99% (may raise to 19.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3082036,"accession_number":"0001493152-26-044248","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-09-25T12:15:15+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"CDT Equity sets 1-for-25 reverse stock split effective Sept 28 to regain Nasdaq bid-price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-25 reverse split effective September 28, 2026 at 5:00 p.m. ET; stock begins trading split-adjusted on Nasdaq on September 29, 2026 under existing ticker CDT.","Outstanding common stock will drop to approximately 1,124,515 shares; par value stays $0.0001 and new CUSIP is 20678X700.","No fractional shares issued; stockholders due a fraction receive cash equal to the fraction times the September 28, 2026 Nasdaq closing price.","Company states the split is to ensure continued compliance with the Nasdaq bid-price rule; stockholders had pre-approved future splits and gave the board authority over timing and ratios.","Proportional adjustments made to equity awards, convertible securities, warrants and exercise prices, plus shares authorized/reserved under equity incentive plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2963876,"accession_number":"0001493152-26-043398","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-09-18T21:15:32+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CDT Equity issues $2.13M convertible note to J.J. Astor; 3.47M warrants at $0.25","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2,126,250 senior secured convertible note to J.J. Astor; $1,575,000 funded (net $1,501,850); 24 weekly payments of $88,593.75 to March 1, 2027.","Warrants to buy 3,468,500 shares at $0.25; conversion at greater of 70% of 20-day VWAP or $0.05 floor price (4.99% ownership cap).","Note secured by first-priority lien; 80% of ATM proceeds after Sept 15, 2026 prepay this note; Aug 31, 2026 note fully repaid Sept 4.","Conversion and warrant issuance require stockholder approval; meeting to be held by Oct 31, 2026 if requested by lender."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2685408,"accession_number":"0001493152-26-041533","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-09-04T20:05:22+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CDT Equity amends Sarborg purchase terms, issues warrants to J.J. Astor","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment to Sarborg agreement: $1.75M of $8M consideration to be paid in common stock; 650,000 shares issued Aug 31, 2026.","Remaining $5.5M cash consideration to be paid from ATM proceeds, min $150k/month, due by May 31, 2027.","Company to pay Sarborg audit costs for FY2024, FY2025, pro-forma 2026, credited against cash consideration.","Issued senior secured convertible note to J.J. Astor & Co. for $541,620 principal, funded $401,200; note repaid in full on Sept 4, 2026.","Issued warrants to purchase 237,000 shares at $1.69, exercisable immediately, expire in 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2604357,"accession_number":"0001493152-26-041016","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-09-01T20:15:24+00:00","items":["8.01"],"status":"ready","headline":"CDT Equity resolves Nasdaq deficiency after cashless exercise of pre-funded warrants","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Investors exercised all 12,131,770 pre-funded warrants cashless; company issued 12,131,122 shares of common stock.","Total shares outstanding 13,693,866 as of Aug 31, 2026; market cap ~$23.0M based on closing price.","Stockholders' equity ~$103M per Q2 10-Q; company states no outstanding Nasdaq deficiencies remain.","Warrants stem from July 30, 2026 purchase agreement with Sarborg Limited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2586559,"accession_number":"0001493152-26-040929","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-09-01T12:00:25+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CDT Equity appoints James Bligh CEO; shareholders approve reverse split","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Bligh appointed CEO effective Aug 31, 2026; retains CFO role until successor named.","Dr. Andrew Regan resigned as CEO and director; gets $50k/month for 6 months severance.","Stockholders approved reverse stock split up to 1-for-500 aggregate and share issuances under Nasdaq rules.","Bligh employment: $600k base salary, 50% target bonus, 12-month notice period, Cayman law.","Board reduced from 5 to 4 members following Regan's resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2393596,"accession_number":"0001493152-26-039588","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K/A","filed_at":"2026-08-21T13:27:55+00:00","items":["9.01"],"status":"ready","headline":"CDT Equity files Sarborg acquisition financials: FY25 revenue $4.6M, net loss $508K, going concern risk","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sarborg FY2025 revenue $4.626M vs $98K in 2024 (inception Oct 28, 2024); net loss $508K vs $282K.","Sarborg had $10K cash and $790K accumulated deficit at Dec 31, 2025; founder guaranty covers cash shortfalls for 18 months.","Sarborg is an agentic AI platform decoding biological, chemical, industrial signatures for drug repurposing and disease insights.","CDT filed unaudited pro forma condensed consolidated statements giving effect to the Sarborg investment (Exhibit 99.3).","Unaudited interim Sarborg financials for six months ended June 30, 2026 filed as Exhibit 99.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2393556,"accession_number":"0001493152-26-039587","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K/A","filed_at":"2026-08-21T13:27:22+00:00","items":["2.01","9.01","1.01","3.02"],"status":"ready","headline":"CDT Equity files amended 8-K for Sarborg investment; Sarborg 2025 revenue $4.6M, net loss $508K","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sarborg FY2025 revenue $4.6M, gross profit $4.2M, net loss $508K (vs. $98K revenue, $282K loss in 2024).","Sarborg had $10K cash and $790K accumulated deficit at 12/31/25; going-concern doubt mitigated by founder guaranty.","CDT's initial investment in Sarborg completed; audited financials and unaudited pro forma statements now filed as Exhibits 99.1/99.2.","Sarborg is an agentic AI platform for drug repurposing and industrial signature analysis; material related-party revenue and deferred revenue.","CDT's common stock (CDT) and warrants (CDTTW) trade on Nasdaq; no deal terms or acquisition price disclosed in this amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2106799,"accession_number":"0001493152-26-036361","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-08-06T20:30:16+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CDT Equity amends convertible note, principal to $2.54M, 19% interest, issues warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal increased to $2,536,650 via second and third amendments; interest rate set at 19% per annum.","Conversion price lowered to 70% of 20-day VWAP (from 90% of 10-day); floor price set at 20% of 20-day VWAP, adjusting semi-annually.","Lender issued warrants to purchase 37,500 shares at $7.20 per share.","ATM net proceeds to lender increased from 80% to 90% to pay weekly installments of $104,187.65 through Jan 20, 2027.","Company must obtain stockholder approval by Aug 28, 2026 for conversion shares exceeding 19.99% of outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2024602,"accession_number":"0001493152-26-035831","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K/A","filed_at":"2026-08-03T20:15:42+00:00","items":["2.01","1.01","3.02","9.01"],"status":"ready","headline":"CDT Equity files amendment to 8-K for Sarborg Limited investments; financial statements deferred","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Amendment No. 1 to original 8-K dated July 30, 2026, filed to include Items 2.01, 9.01(a), and 9.01(b) regarding Sarborg Limited investments.","Financial statements and pro forma financial information for the acquisition will be filed via additional amendment within 71 days.","No new material financial or operational details provided in this amendment; specifics of the transaction are in the original report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1997716,"accession_number":"0001493152-26-035682","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-07-31T21:26:20+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CDT Equity acquires 4.76% stake in Sarborg; issues pre-funded warrants for 12.1M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 270 shares of Sarborg (4.76% of outstanding) from investors in exchange for pre-funded warrants to purchase up to 12,131,770 shares of CDT common stock at $0.0001 per share.","Warrants require stockholder approval before exercise due to exceeding 19.99% of outstanding common stock; company to file resale registration statement within 60 days of closing.","CEO Andrew Regan, also a Sarborg director, participated via his wholly-owned company Corvus Capital, receiving warrants for 5,436,830 shares on same terms as other investors.","Additionally, issued 123,537 shares of common stock to four service providers as consideration for services on July 30-31, 2026.","As of July 30, 2026, company had 663,179 shares of common stock outstanding; the warrant shares represent over 18x current shares if exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1941561,"accession_number":"0001493152-26-035202","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-07-29T20:30:33+00:00","items":["3.02"],"status":"ready","headline":"CDT Equity issues 32,110 shares at $3.27 for consulting services","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Issued 32,110 shares of common stock at $3.27 per share to a service provider.","Total consideration valued at approximately $105,000 for consulting services.","Shares issued under Section 4(a)(2) exemption from registration.","No other material terms disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1674117,"accession_number":"0001493152-26-033455","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-07-16T12:05:43+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"CDT Equity announces 1-for-10 reverse stock split to comply with Nasdaq bid-price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective July 17, 2026 at 5:00 pm ET; trading on split-adjusted basis July 20, 2026.","Every 10 shares of common stock will combine into 1 share; outstanding shares reduced to approx 631,077.","No fractional shares issued; stockholders entitled to fractional shares receive cash payment in lieu.","CUSIP number for post-split common stock changes to 20678X601; ticker symbol remains CDT.","Split intended to ensure continued compliance with Nasdaq minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1501317,"accession_number":"0001493152-26-032375","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-07-07T21:20:44+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CDT Equity amends loan agreement, closes second tranche of $1.46M convertible note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended Loan Agreement and Note executed June 30, 2026; second tranche of $1.46M loan funded.","Weekly installment payments of $82,125 commence July 10, 2026 (previously June 18).","Note principal $1.97M, convertible into common stock at lender's option, subject to 4.99% beneficial ownership cap.","Default triggers 120% principal acceleration and 19% annual interest.","Note matures December 18, 2026; mandatory prepayment from equity or extraordinary receipts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1334079,"accession_number":"0001493152-26-031093","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-06-29T20:30:16+00:00","items":["4.01","9.01"],"status":"ready","headline":"CDT Equity dismisses auditor CBIZ CPAs, engages CRI; cites going concern, material weaknesses","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit committee dismissed CBIZ CPAs and engaged Carr, Riggs & Ingram (CRI) on June 23, 2026.","Prior audit report contained a going-concern explanatory paragraph for the year ended Dec 31, 2025.","Multiple material weaknesses in internal controls were reported, including lack of segregation of duties and inadequate review processes.","No disagreements with CBIZ CPAs on accounting principles during the engagement period.","CBIZ CPAs' letter agreeing with company's statements is filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1085917,"accession_number":"0001493152-26-028909","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-06-16T21:00:18+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"CDT Equity repays $6.3M legacy debt, enters new $1.46M JJ Astor loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $5,737,500 A.G.P. convertible loan notes and $555,556 Ascent Partners note, eliminating over $6.3M in legacy obligations.","New Loan Agreement with JJ Astor & Co for up to $1,460,000; first tranche of ~$268k funded, balance expected in June 2026.","Issued warrants to purchase 912,500 shares at $0.72 per share, exercisable after stockholder approval.","New loan is sole facility; terms include possible conversion at discount to VWAP and weekly installments of $82,125."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":722796,"accession_number":"0001493152-26-025629","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-05-28T20:30:30+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on May 21, 2026 for failing to timely file Q1 2026 Form 10-Q under Listing Rule 5250(c)(1).","No immediate effect on listing or trading of common stock (CDT) or warrants (CDTTW).","Must submit a plan to regain compliance by July 20, 2026.","Company anticipates filing Form 10-Q shortly upon completion of the current draft review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470359,"accession_number":"0001493152-26-023707","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-05-15T20:01:42+00:00","items":["1.01","9.01"],"status":"ready","headline":"CDT Equity amends ELOC and convertible note; retains 90% of future proceeds, sets $510K purchase cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 2 caps regular ELOC purchase at $510,000 without purchaser consent; extends adjustment period until all shares sold.","Note Amendment allows CDT to retain 90% of proceeds from future financings; only 10% goes toward the convertible note.","Both amendments expire May 31, 2026, applying only to May 2026 transactions.","Amendments were with institutional investor Ascent Partners Fund LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96618,"accession_number":"0001493152-26-019133","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CDT Equity appoints Ulrik Olsen to board; Freda Lewis-Hall resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Freda Lewis-Hall resigned from board on April 27, 2026 for family health reasons; no disagreement with company.","Ulrik Olsen appointed as director and member of Audit, Compensation, and Nominating Committees.","Chele Chiavacci Farley named board chair and Nominating Committee chair; Simon Fry appointed Audit Committee chair.","Olsen, age 50, is a NZ-based property executive and holds ~7.84% ownership in Sarborg Ltd., a company in which CDT holds 20% equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110670,"accession_number":"0001493152-26-012538","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"CDT Equity Inc. announces 1-for-25 reverse stock split effective March 26, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:25 ratio; effective March 26, 2026 at 5:00 pm ET.","Common stock to trade split-adjusted under ticker CDT from March 27, 2026.","Outstanding shares reduced to approximately 4,722,450; no fractional shares issued.","Par value unchanged at $0.0001; equity awards and warrants proportionally adjusted.","Stockholders need not take action; positions adjusted automatically by brokers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110669,"accession_number":"0001493152-26-011270","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CDT Equity stockholders approve redomestication to Cayman Islands, reverse stock split, and share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redomestication from Delaware to Cayman Islands approved (Proposal 6): ~2.22M for, 72K against, 21.9K abstain.","Authorized common shares increased from 250M to 500M (Proposal 5): ~2.23M for, 77K against.","Reverse stock split authorized (Proposal 4) at ratios 1:2 to 1:100 (aggregate 1:250) at board discretion.","Issuance of up to 109.98M shares upon exercise of pre-funded warrants (Proposal 3) and 3.69M shares (Proposal 1) approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110668,"accession_number":"0001493152-26-009367","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CDT Equity lowers ELOC floor to $0.60 and issues $555K convertible note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment cuts ELOC floor price to $0.60; max shares issuable ~41.7M, subject to stockholder approval.","Issued Senior Secured Convertible Promissory Note for up to $555,556 principal at 10% interest, matures July 3, 2026.","Note convertible at Nasdaq closing price on stockholder approval date; secured by assets and guaranteed.","Company must hold stockholders' meeting by May 3, 2026 to approve conversion shares.","Note may be prepaid on 10 days' notice; mandatory prepayment upon equity offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110667,"accession_number":"0001493152-26-007906","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CDT Equity acquires 20% of Sarborg for stock, warrants, deferred $8M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 1,020 Sarborg shares (~20% stake) in exchange for 598,006 shares + pre-funded warrants for 109,978,918 shares at $0.0001 exercise price.","Agreed to pay Sarborg $8M cash, deferred until CDT raises ≥$20M via ATM program.","Issued 199,734 shares to NJS Foresight ($150k retainer) and 341,702 shares to Thesprogen ($245k retainer) for consulting extensions.","Issued 130,000 unregistered shares to Maxim Partners for investment banking services.","Directors Andrew Regan and Chele Farley have ties to Sarborg; Farley received 10,533 shares + 1,940,804 warrant shares in the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110666,"accession_number":"0001493152-26-003244","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CDT Equity enters $25M equity line of credit with Ascent Partners; issues 204,031 commitment shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CDT Equity entered a directed stock purchase agreement for up to $25M of common stock with institutional investor Ascent Partners.","Company may draw up to $750K per regular closing or $5M per expanded closing, subject to volume and price conditions.","Initial floor price of $1.35; pricing at 97%/95%/94% of VWAP based on stock price tiers.","As commitment, CDT will issue 204,031 shares to Ascent Partners; registration rights agreement filed to register resale.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110665,"accession_number":"0001493152-26-000143","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CDT enters consulting pacts with Thesprogen and NJS; issues 213,288 shares for $305k in services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thesprogen will evaluate AZD1656 pre-clinical data and optimize development strategies; 6-month term, $155k fee paid in 108,392 shares.","NJS to identify out-licensing partners for solid-form patent portfolio; $150k retainer in 104,896 shares plus 8% commission on transactions.","Shares issued in unregistered transaction under Regulation D; no registration rights granted.","Press release highlights NJS engagement to accelerate licensing and royalty-based deals for solid-form assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127292,"accession_number":"0001493152-25-027489","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CDT sells CPL subsidiary to CEO affiliate Corvus for $7M to offload Strand litigation liability","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CDT sells CPL to Corvus Capital (wholly-owned by CEO Andrew Regan) for $7M in common stock or pre-funded warrants.","Settlement of 3,910,615 shares at $1.79; beneficial ownership capped at 19.99%, warrants subject to shareholder approval up to 49.99%.","Corvus indemnifies CDT for any adverse judgment in Strand Hanson litigation (trial concluded Oct 28, 2025).","If CPL wins cost recovery, Corvus pays CDT the lesser of $1M or recovered costs.","CDT to file resale registration statement within 60 days for the issued shares/warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127291,"accession_number":"0001493152-25-017533","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"CDT Equity announces 1-for-8 reverse stock split effective October 10, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split of every 8 shares into 1, effective Oct 10, 2025 at 5:00 PM ET.","Common stock will begin trading on split-adjusted basis Oct 13 under symbol CDT, new CUSIP 20678X403.","Outstanding shares reduced to approximately 1,352,448; par value remains $0.0001.","No fractional shares issued; fractional holders receive cash based on closing price on effective date.","Stockholders approved reverse split authority on May 5, 2025; board set ratio at 1-for-8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144082,"accession_number":"0001641172-25-023840","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"CDT Equity restates Q1 2025 financials; $0.4M milestone misclassified as R&D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 8, 2025, CDT Equity determined its unaudited Q1 2025 financials should no longer be relied upon.","$0.4 million in milestone payments to Sarborg Limited were misclassified as R&D expense instead of an acquired diagnostic asset.","The restatement requires amendments to the Q1 2025 10-Q, affecting balance sheet, income statement, and cash flows.","The Audit Committee and independent accounting firm CBIZ CPAs agreed on the restatement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144081,"accession_number":"0001641172-25-022760","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.02","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.","James Bligh, co-founder and interim CFO since May 2024, appointed permanent CFO; compensation unchanged; retains board seat.","Stockholders approved amendment to 2023 Stock Incentive Plan adding 2,000,000 authorized shares for awards.","Press release details strategic shift: AI-driven drug repurposing via Sarborg partnership, animal health collaboration with Manoira, and evaluation of cryptocurrency treasury reserve strategy.","All five director nominees elected: Andrew Regan, Freda Lewis-Hall, James Bligh, Chele Chiavacci Farley, Simon Fry; auditor CBIZ CPAs P.C. ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162386,"accession_number":"0001641172-25-014322","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Conduit enters joint development with Manoira for AZD1656/AZD5658 in animal health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Conduit grants Manoira non-exclusive license to AZD1656 and AZD5658 for veterinary use; Manoira funds development.","Conduit issued 154,799 shares at $3.23/share (~$500K) to Manoira, a company controlled by CEO Andrew Regan.","Initial evaluation focuses on AZD1656 in canine osteoarthritis; plans combination with patented CBDA co-crystal.","Conduit retains all human IP and data ownership; agreement provides cross-species translational data for human programs.","Collaboration targets potential revenue in $15B animal health market (6.5% CAGR through 2027)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162385,"accession_number":"0001641172-25-013468","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Conduit Pharmaceuticals sets 2025 annual meeting for Aug 5; proxy deadlines June 17","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for August 5, 2025; record date is July 3, 2025.","Stockholder proposals for proxy inclusion must be received by June 17, 2025.","Director nominations and other business proposals also due by June 17, 2025 per bylaws.","Meeting date is more than 30 days before anniversary of 2024 meeting, triggering this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162384,"accession_number":"0001641172-25-011183","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals announces 1-for-15 reverse stock split effective May 19, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-15 reverse split effective May 19, 2025 at 5:00 p.m. ET; split-adjusted trading begins May 20 under ticker CDT.","Post-split outstanding shares reduced to approximately 755,900 from roughly 11.3 million pre-split.","No fractional shares issued; cash payment in lieu at closing price on May 19.","Par value unchanged at $0.0001; new CUSIP number 20678X 304; warrants and equity awards proportionally adjusted.","Stockholders approved reverse split at special meeting on May 5, 2025; board set exact ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162383,"accession_number":"0001641172-25-008854","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Conduit Pharma stockholders approve reverse stock split up to 1-for-250 at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal passed with 5,065,868 votes for, 496,473 against, 1,438 abstentions.","Board may implement split at ratios from 1-for-2 to 1-for-100, aggregate not exceeding 1-for-250.","The reverse stock split amendments to the certificate of incorporation have been authorized.","Company's common stock trades under CDT on Nasdaq; warrants trade under CDTTW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162382,"accession_number":"0001641172-25-006224","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals changes auditor from Marcum to CBIZ CPAs; going concern and material weaknesses cited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 24, 2025; CBIZ CPAs P.C. appointed on April 25, 2025.","Audit reports for FYE 2024 and 2023 included a going concern explanatory paragraph due to substantial doubt.","Material weaknesses in internal controls identified: inadequate segregation of duties, lack of review controls, restatement.","No accounting disagreements between Company and Marcum; no reportable events except the material weaknesses noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162381,"accession_number":"0001641172-25-005036","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Conduit Pharma appoints founder Andrew Regan as CEO; Tapolczay transitions to licensing role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Tapolczay resigned as CEO and board member effective April 12, 2025; to serve as Head of Licensing & Strategy at £240K salary.","Andrew Regan appointed CEO effective April 15, 2025; continues as director and waives compensation except expense reimbursement.","Faith Charles resigned from board effective April 16, 2025 for personal reasons; board reduced from seven to five members.","Tapolczay to focus on out-licensing tapinarof patents; Regan highlights AI collaboration with Sarborg and 20-year patent strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162380,"accession_number":"0001641172-25-002774","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Conduit Pharmaceuticals enters AI analytics deal for AstraZeneca assets; issues 2.26M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered additional agreement with Sarborg for AI analysis of AZD1656, AZD5658, AZD5904 clinical data to identify repurposing opportunities.","Agreement term six months, total consideration $2.0M (cash or stock at company's election).","Issued 1,853,933 shares to satisfy ~$1.65M of fees; also issued 410,113 shares for consulting services.","Company had 9,549,800 shares outstanding as of March 31, 2025.","Aim is to re-evaluate failed endpoints from AstraZeneca trials to identify benefited patient subgroups."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162378,"accession_number":"0001641172-25-002400","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K/A","filed_at":"2025-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Conduit Pharmaceuticals regains full Nasdaq compliance after $8.3M raise and debt conversion","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted pro-forma financials showing stockholder's equity of $2.8M vs $2.5M minimum required.","Raised $8.332M from at-the-market offering; converted $1.785M debt into 924,200 shares.","Compliant with Market Value of Publicly Held Securities standard (>$1M) as of March 7, 2025.","Nasdaq Capital Market Equity Standard compliance achieved as of March 31, 2025 and continuing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162379,"accession_number":"0001641172-25-002147","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Conduit Pharmaceuticals provides Nasdaq compliance update; equity above $2.5M threshold","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Submitted pro-forma financials showing Stockholder's Equity of $2.8M as of March 31, 2025, above Nasdaq's $2.5M minimum.","Currently compliant with Market Value of Publicly Held Securities standard (>$1.0M).","Application to transfer to Nasdaq Capital Market was made on March 7, 2025.","CEO David Tapolczay signed the report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180398,"accession_number":"0001493152-25-009330","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Conduit Pharmaceuticals receives Nasdaq extension, plans transfer to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearing Panel granted extension to March 31, 2025 to regain MVPHS and MVLS compliance.","Company must file application to transfer to Nasdaq Capital Market by March 12, 2025.","Bid Price compliance regained as of February 26, 2025; extension conditional on meeting all listing rules.","Company believes it can satisfy equity standard of >$2.5M stockholder's equity before deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180397,"accession_number":"0001493152-25-007573","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["1.02","8.01","3.01"],"status":"ready","headline":"Conduit Pharmaceuticals repays $926k note, receives Nasdaq delisting basis for continued listing deficiencies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid remaining $926,149 on Senior Note to Nirland Limited on Feb 13, 2025; all assets now free of liens.","On Feb 12, 2025, Nasdaq notified Conduit it did not regain compliance with MVPHS and MVLS requirements; added as delisting bases.","Company presented compliance plan to Nasdaq Hearing Panel on Feb 11; awaiting determination; no assurance of continued listing.","Original Senior Note was $2,650,000 ($500k OID); full satisfaction removes all security interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180396,"accession_number":"0001493152-25-005796","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Conduit Pharmaceuticals repays $600K note; lender converts $1.7M Senior Note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid full principal of $600,000 promissory note on Feb 7, 2025; note bore 12% interest and matured Oct 31, 2025.","Nirland Limited converted ~$1.7M of $2.65M Senior Note principal into common shares as of Feb 10, 2025.","Senior Note issued Aug 6, 2024 with 12% interest and $500,000 original issuance discount.","Both transactions reduce Conduit's outstanding debt obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180395,"accession_number":"0001493152-25-003316","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals announces 1-for-100 reverse stock split to meet Nasdaq bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Jan 24, 2025 at 5pm ET; shares begin trading on split-adjusted basis Jan 27 under ticker CDT.","Every 100 shares combined into 1; no fractional shares; cash in lieu for fractional interests.","Post-split outstanding shares reduced to approximately 1.5 million.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180394,"accession_number":"0001493152-25-002176","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Conduit shareholders approve issuance of up to 135.9M shares via warrant exercises and note conversions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 1: approved 2,862,596 shares from warrant exercise (38.1M for, 1.5M against).","Proposal 2: approved up to 75M shares from Nirland Limited note conversion (35.0M for, 4.6M against).","Proposal 3: approved up to 58M shares from A.G.P./Alliance Global Partners note conversion (35.0M for, 4.6M against).","All proposals passed with >35M votes for each; no broker non-votes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197221,"accession_number":"0001493152-24-051089","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["3.01","5.02","5.07"],"status":"ready","headline":"Nasdaq notifies Conduit of delisting due to low price; shareholders approve reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price ≤ $0.10 for 10 consecutive days; delisting set for Dec 27 unless hearing requested.","Company intends to request a hearing before Nasdaq Hearings Panel; delisting stayed pending decision.","Stockholders approved a reverse stock split at ratio between 1-for-10 and 1-for-100 at Dec 18 annual meeting.","Simon Fry appointed director and Audit Committee member; granted option for 420,000 shares on Dec 18.","Nasdaq confirmed compliance with audit committee requirements after Fry's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197220,"accession_number":"0001493152-24-050443","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Conduit signs AI services deal with Sarborg; upfront $400K, up to $1.8M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with SARBORG for algorithmic AI/cybernetics services to optimize drug development, repurposing, and clinical trials.","Initial consideration: $200,000 cash + $200,000 via 2,272,727 shares (based on closing price on Dec 11).","Milestone payments up to $1.8M payable in cash or shares at Conduit's discretion.","Board member Dr. Andrew Regan serves on both boards (related party transaction).","Services span three phases: initial (0-24 weeks), development (24-36 weeks), ongoing (36-52 weeks)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197219,"accession_number":"0001493152-24-047631","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Conduit Pharma issues $5.74M convertible note to A.G.P. and amends Nirland note; conversion needs stockholder approval","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $5,737,500 convertible note to A.G.P. for deferred commission; 5.5% interest, matures Nov 25, 2025.","Second Amendment to $2.65M Nirland note restricts conversion until stockholder approval; $100K/day penalty if meeting not held by Jan 9, 2025.","Conversion price $0.10/share (adjusted for reverse splits); up to 75M shares (Nirland) and 58M shares (A.G.P.) issuable upon conversion.","Both notes require stockholder approval under Nasdaq rules before conversion can occur.","Company can prepay notes; customary default provisions included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197218,"accession_number":"0001493152-24-046849","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Conduit Pharma appoints director Fry (420K options); amends CFO pay (£400K, 40% bonus) and quorum rule","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Fry appointed as director effective Dec 18, 2024; receives initial option for 420,000 common shares.","CFO James Bligh's employment amendment: £400K base salary, discretionary bonus up to 40%, 6-month notice.","Bylaws amended: quorum reduced from majority to one-third voting power, effective after 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197217,"accession_number":"0001493152-24-046068","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Conduit Pharmaceuticals restates Q1 and Q2 2024 financials; reclassifies deferred commission to current liability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Previously issued unaudited financials for Q1 and Q2 2024 should no longer be relied upon due to reclassification error.","Restatement reclassifies deferred commission payable from long-term to current liability; no impact on total liabilities.","Company will file amendments to its Q1 and Q2 2024 Forms 10-Q to correct the balance sheet classification.","Discussions with auditor Marcum LLP and Audit Committee led to the non-reliance determination on November 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197216,"accession_number":"0001493152-24-043330","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Conduit Pharmaceuticals secures $1.2M in new loans; issues warrants and amends existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Bridge Loan with A.G.P. for up to $600k at 4.21% due Dec 31, 2024; issued warrants for 2.86M shares at $0.1048 per share, subject to shareholder approval.","Issued $600k promissory note to Nirland Limited at 12% per annum, maturing Oct 31, 2025; includes 1% arrangement fee.","Amended prior $2.65M Nirland note to allow conversion to common stock and removed mandatory prepayment and right of first refusal.","Proceeds from ATM offering of up to ~$3.5M will be used first to repay the A.G.P. Bridge Note.","Warrants and conversion shares are unregistered, issued under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197215,"accession_number":"0001493152-24-041154","cik":1896212,"company_name":"CDT Equity Inc.","ticker":"CDT","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Conduit extends $800K convertible note, issues 2.78M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Original $800K convertible note (20% interest) due Sept 20, 2024 amended; maturity extended to Oct 20, 2024, with possible further 30-day extensions.","On Oct 11, 2024, issued 2,781,250 shares of common stock: $80K worth at market price plus 2,000,000 shares.","Payees waived all previously due interest and principal payments; all now due on new Repayment Date.","Company may further extend maturity to Nov 19 or Dec 19, 2024 at its discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5344185.1181725655,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-10-15T23:59:59+00:00|197215"}